Hair Loss News and Research

RSS

Mycophenolate mofetil is effective for managing symptoms of the most common type of lupus

Mayo Clinic investigators have found that the medication mycophenolate mofetil is effective for managing symptoms of systemic lupus erythematosus (SLE), the most common type of lupus, for patients whose SLE does not affect the kidneys.

18 Oct 2004

Options for women experiencing hair loss

Each year, women spend countless hours and dollars on their hair. It can play a major role in a woman’s self-confidence and self-esteem, making female pattern hair loss a potentially debilitating condition, socially and emotionally. But it doesn’t have to be.

13 Oct 2004

Women with the Polycystic Ovary Syndrome (PCOS) are at greatest risk for diabetes and coronary artery disease

A new position statement issued today by the American Association of Clinical Endocrinologists (AACE) states that women with the Polycystic Ovary Syndrome (PCOS) are at greatest risk for diabetes and coronary artery disease.

6 Oct 2004

Painful and damaging chemotherapy may one day be a thing of the past

Researchers at the Georgia Institute of Technology and Purdue University have developed nano-sized particles that can target and trick cancer cells into absorbing them.

10 Sep 2004

Knowledge about oral and head and neck cancer is severely lacking in the American public

Most adult Americans know how to light a cigarette and order a drink, but a great number of them are clueless about the consequence of these two destructive habits – oral and head and neck cancer.

9 Aug 2004

The Woods Technique of Follicular Relocation - single hair follicle transplant micro-surgery

The doctors who first researched, developed and perfected single hair follicle transplant micro-surgery announced today that they are bringing their remarkable technique to the United States. And they are backing it up with a published "Declaration of Patient's Rights."

2 Aug 2004

Alimta receives positive endorsement for lung cancer approval from FDA Advisory Committee

Eli Lilly and Company have announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration positively endorsed Alimta® (pemetrexed), an antifolate, for accelerated approval in the second-line treatment of non-small cell lung cancer.

29 Jul 2004

Educating patients can help limit side effects of chemotherapy and radiation

A new study finds patients about to undergo chemotherapy or radiation expect a high number of side effects, and that age, gender, educational background, and the type of cancer all influence how many side effects a patient expects.

12 Jul 2004

Hair cloning could be the cure for baldness

Researcher Kevin McElwee -- one of only a few people in the world who hold a doctoral degree in hair biology -- thinks a cure for baldness that uses the technique of hair cloning could be commercially available within 10 years.

24 Jun 2004

For nearly 50% of women, hair loss was the most distressing side effect of chemotherapy

Information and support charity CancerBACUP has dramatically revised its booklet on hair loss - the most traumatic side effect of cancer treatment for many women. The revamped booklet also now includes practical advice for patients from minority ethnic groups.

14 Jun 2004

Docetaxel decreases the chance of dying by 24 percent in advanced-stage prostate cancer patients resistant to hormone therapy

Johns Hopkins Kimmel Cancer Center clinicians were among those at leading institutions that have completed a three-year international study showing that docetaxel, a drug made from yew tree needles, decreases the chance of dying by 24 percent in advanced-stage prostate cancer patients resistant to hormone therapy.

11 Jun 2004

$First drug approved for hormone refractory prostate cancer that has shown a survival benefit$

First drug approved for hormone refractory prostate cancer that has shown a survival benefit

The the Food and Drug Administration (FDA) approved Taxotere (docetaxel), injection in combination with prednisone ( a steroid), for the treatment of patients with advanced metastatic prostate cancer. This is the first drug approved for hormone refractory prostate cancer that has shown a survival benefit.

19 May 2004

Interventional radiologists now are able to treat using minimally invasive procedures

Interventional radiologists at Temple University Hospital now are able to treat many patients with minimally invasive procedures not available only a few years ago. “Conditions that used to require extensive surgery now take an hour or less, and patients leave with a bandaid and walk home,” says Gary Cohen, M.D., Section Chief of Interventional Radiology and Vice Chairman of Radiology. “How can you beat that?”

17 May 2004

New developments in the treatment of pancreatic cancer

A booster dose of a substance already found in the body appears to be safe and non-toxic for the treatment of pancreatic cancer, and shows signs of arresting pancreatic cancer cell growth in patients, Penn State College of Medicine researchers report.

20 Apr 2004

Thyroid disorders are often misdiagnosed

Thyroid disorders are among the most common medical conditions. However, because their symptoms often appear gradually, the condition is often misdiagnosed, according to Dr. Nila Vora, a board-certified endocrinologist at the Loyola Primary Care Center in Darien.

25 Mar 2004